RecruitingNot ApplicableNCT06165302
Exercise in Prostate Cancer
EPC Trial: Exercise in Prostate Cancer
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Enrollment
20 participants
Start Date
Oct 16, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn how exercise intervention affects circulating tumor cells (CTC) in men with advanced prostate cancer. The primary objective is to determine if an exercise intervention decreases CTCs in men with advanced prostate cancer. Participants will have baseline screening assessments, followed by 12 weeks of exercise intervention, and then follow-up assessments 12 weeks after the end of the exercise intervention.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria9
- Men with metastatic prostate adenocarcinoma
- Currently taking androgen deprivation therapy alone or with an oral androgen axis inhibitor (abiraterone, enzalutamide, darolutamide, or apalutamide are permitted) and have been on treatment for at least 3 months
- Elevated (PSA \> 1ng/mL) or rising PSA (any numerical increase based on at least 2 PSA readings at least 2 weeks apart)
- Any number of prior therapies (prior chemo, radium-223, etc.) is allowed
- CTC + according to standard clinical grade laboratory test by androgen receptor isoform splice variant 7 (AR-V7) testing at Hopkins.
- If a bone protective agent is to be started, it should be started at least 2 weeks prior to the onset of exercise intervention.
- Eastern Cooperative Oncology Group (ECOG) performance status \<=1
- Clearance by cardiologist if under the current care of a cardiologist (seen in the past 1 year)
- Age \<=80 years
Exclusion Criteria7
- Small cell carcinoma of the prostate
- Unable to participate or monitor exercise compliance due to conditions such as impaired cognition
- Moderate to severe bone pain that limits any activities of daily living, including use of narcotics for prostate cancer related pain
- Clinical progression requiring a change in systemic therapy or the addition of palliative radiation for symptom control
- Bone metastases in spine or long bones which, in the eye of the treating physician require referral to radiation oncology or surgery for management due to risk of fracture
- Significant cardiovascular disease or concurrent illness that would make exercise intervention for 12 weeks unsafe. If there is significant cardiovascular disease and the participant is under the care of a cardiologist (seen within the past 1 year), approval of the cardiologist to participate is required.
- Major surgery within the past 4 weeks
Interventions
BEHAVIORALExercise Intervention
12 weeks of prescribed exercise intervention.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06165302
Related Trials
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT054354953 locations
Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
NCT0489583916 locations
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT0678067052 locations